Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


The Glycogen Synthase Kinase-3β Inhibitor LSN 2105786 Promotes Zebrafish Fin Regeneration.

Sarmah S, Curtis C, Mahin J, Farrell M, Engler TA, Sanchez-Felix MV, Sato M, Ma YL, Chu S, Marrs JA.

Biomedicines. 2019 Apr 19;7(2). pii: E30. doi: 10.3390/biomedicines7020030.


Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor.

Wijeratne A, Xiao J, Reutter C, Furness KW, Leon R, Zia-Ebrahimi M, Cavitt RN, Strelow JM, Van Horn RD, Peng SB, Barda DA, Engler TA, Chalmers MJ.

ACS Med Chem Lett. 2018 May 21;9(6):557-562. doi: 10.1021/acsmedchemlett.8b00110. eCollection 2018 Jun 14.


Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3.

Atkinson JM, Rank KB, Zeng Y, Capen A, Yadav V, Manro JR, Engler TA, Chedid M.

PLoS One. 2015 Apr 27;10(4):e0125028. doi: 10.1371/journal.pone.0125028. eCollection 2015.


A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators.

Sutherland JJ, Low J, Blosser W, Dowless M, Engler TA, Stancato LF.

Mol Cancer Ther. 2011 Feb;10(2):242-54. doi: 10.1158/1535-7163.MCT-10-0720. Epub 2011 Jan 7.


Changes in osteoblast, chondrocyte, and adipocyte lineages mediate the bone anabolic actions of PTH and small molecule GSK-3 inhibitor.

Kulkarni NH, Wei T, Kumar A, Dow ER, Stewart TR, Shou J, N'cho M, Sterchi DL, Gitter BD, Higgs RE, Halladay DL, Engler TA, Martin TJ, Bryant HU, Ma YL, Onyia JE.

J Cell Biochem. 2007 Dec 15;102(6):1504-18.


The development of potent and selective bisarylmaleimide GSK3 inhibitors.

Engler TA, Malhotra S, Burkholder TP, Henry JR, Mendel D, Porter WJ, Furness K, Diefenbacher C, Marquart A, Reel JK, Li Y, Clayton J, Cunningham B, McLean J, O'toole JC, Brozinick J, Hawkins E, Misener E, Briere D, Brier RA, Wagner JR, Campbell RM, Anderson BD, Vaughn R, Bennett DB, Meier TI, Cook JA.

Bioorg Med Chem Lett. 2005 Feb 15;15(4):899-903.


Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.

Engler TA, Henry JR, Malhotra S, Cunningham B, Furness K, Brozinick J, Burkholder TP, Clay MP, Clayton J, Diefenbacher C, Hawkins E, Iversen PW, Li Y, Lindstrom TD, Marquart AL, McLean J, Mendel D, Misener E, Briere D, O'Toole JC, Porter WJ, Queener S, Reel JK, Owens RA, Brier RA, Eessalu TE, Wagner JR, Campbell RM, Vaughn R.

J Med Chem. 2004 Jul 29;47(16):3934-7.


Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitors.

Zhu G, Conner SE, Zhou X, Chan HK, Shih C, Engler TA, Al-Awar RS, Brooks HB, Watkins SA, Spencer CD, Schultz RM, Dempsey JA, Considine EL, Patel BR, Ogg CA, Vasudevan V, Lytle ML.

Bioorg Med Chem Lett. 2004 Jun 21;14(12):3057-61.


Synthetic approaches to indolo[6,7-a]pyrrolo[3,4-c]carbazoles: potent cyclin D1/CDK4 inhibitors.

Faul MM, Engler TA, Sullivan KA, Grutsch JL, Clayton MT, Martinelli MJ, Pawlak JM, LeTourneau M, Coffey DS, Pedersen SW, Kolis SP, Furness K, Malhotra S, Al-awar RS, Ray JE.

J Org Chem. 2004 Apr 30;69(9):2967-75.


Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.

Engler TA, Furness K, Malhotra S, Sanchez-Martinez C, Shih C, Xie W, Zhu G, Zhou X, Conner S, Faul MM, Sullivan KA, Kolis SP, Brooks HB, Patel B, Schultz RM, DeHahn TB, Kirmani K, Spencer CD, Watkins SA, Considine EL, Dempsey JA, Ogg CA, Stamm NB, Anderson BD, Campbell RM, Vasudevan V, Lytle ML.

Bioorg Med Chem Lett. 2003 Jul 21;13(14):2261-7.


Tandem 5 + 2/3 + 2 and 5 + 2/3 + 3 Cycloaddition Reactions.

Engler TA, Scheibe CM, Iyengar R.

J Org Chem. 1997 Nov 28;62(24):8274-8275. No abstract available.


Supplemental Content

Loading ...
Support Center